CJC-1295 and athlete drug testing: what gets caught

Last updated 2026-07-26

Is CJC-1295 banned in competitive sports?

Yes. The World Anti-Doping Agency lists growth hormone releasing factors, which includes GHRH analogues like CJC-1295, under section S2 of the Prohibited List, alongside growth hormone itself, GH secretagogues, and related peptides ^[1]. The 2024 Prohibited List states that S2 covers "Growth Hormone (GH) and its releasing factors" including "Growth Hormone Releasing Hormone (GHRH) and its analogues (e.g. CJC-1295, sermorelin, tesamorelin)" ^[1]. This category is banned at all times, in and out of competition. That matters because it means an athlete can't just time a cycle to clear before a meet the way some stimulant users try to do. If you're subject to WADA-code testing (Olympic sports, most national federations, many college and pro leagues that adopt WADA-aligned rules), CJC-1295 use is a violation whenever it happens, tested or not. Ipamorelin, the growth hormone releasing peptide almost always paired with CJC-1295, falls under the same S2 category as a GH secretagogue. Using both together doesn't create some loophole; it's two banned substances instead of one.

Does CJC-1295 show up on a standard drug test?

No, not on the panels most people mean when they say "drug test." A standard 5-panel or 10-panel workplace test screens for THC, cocaine, opiates, amphetamines, PCP, and sometimes benzodiazepines or barbiturates. Peptide hormones aren't part of that chemistry and never will be, because the assay methods are completely different (immunoassay screens tuned to small molecules of abuse, not peptide sequences). DOT-regulated testing under 49 CFR Part 40 follows the same logic: it targets the substances specified by the Federal Motor Carrier Safety Administration and other DOT agencies, and growth hormone secretagogues aren't on that list ^[2]. If you're a commercial driver, pilot, or other DOT-covered employee, a CJC-1295 cycle will not appear on your DOT test. The only people who need to worry about detection are athletes under a WADA-code testing program, or in a handful of other elite sport contexts (some pro leagues run their own peptide-specific screens). Everyone else is not being tested for this, full stop.

How do anti-doping labs actually detect CJC-1295?

WADA-accredited labs use targeted mass spectrometry methods built specifically for peptide hormones, not the generic immunoassays used in workplace testing. Detecting a synthetic GHRH analogue means looking for its specific amino acid sequence or characteristic fragment ions, since CJC-1295 isn't naturally present in the body the way endogenous GHRH is. The World Anti-Doping Agency also runs the Athlete Biological Passport (ABP), which since 2009 has included modules that track individual biomarkers over time rather than looking for a single drug molecule ^[3]. For growth hormone doping specifically, the ABP framework and related GH isoform tests look for the ratio shifts and downstream markers (IGF-1, P-III-P) that GH and GH secretagogues push around, rather than trying to catch the drug itself in a single sample ^{[3] [4]}. This two-pronged approach (direct detection plus passport-style biomarker tracking) is why athletes can't assume a short peptide has a short detection window the way, say, alcohol does. A single clean urine sample doesn't clear you if your longitudinal blood markers show a pattern consistent with GH-axis manipulation.

What is the actual detection window for CJC-1295?

Nobody has published a definitive, universally-cited detection window for CJC-1295 the way there is for, say, THC. The honest answer is that it depends heavily on which version was used and the assay sensitivity of the specific lab. CJC-1295 without DAC (sometimes called mod GRF 1-29) has a short plasma half-life, on the order of 30 minutes, so parent-drug detection in blood or urine likely closes within a day or so after the last dose ^[5]. CJC-1295 with DAC, the version bound to a Drug Affinity Complex that attaches to serum albumin, has a half-life reported around 6 to 8 days in the original pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism ^[6]. That means detectable drug (or at least its distinctive fragments) can plausibly persist for one to two weeks after a single administration, and longer with repeated dosing. But direct detection windows are only half the story. Because of the biological passport, downstream effects on IGF-1 and GH pulsatility can remain flagged as abnormal well beyond the point where the parent peptide itself is gone. There's no forum number worth trusting here; treat any specific "it clears in X days" claim as folklore unless it cites an actual pharmacokinetic study.

What is the difference between CJC-1295 with DAC and without DAC, and does it change testing risk?

CJC-1295 with DAC and CJC-1295 without DAC are the same core GHRH analogue peptide, but the DAC version has a chemical tail (the Drug Affinity Complex) that lets it bind circulating albumin, dramatically slowing clearance from about 30 minutes to roughly a week ^[6]. This is a real, published pharmacokinetic distinction, not marketing. For testing purposes, both fall under the same WADA S2 category, so there's no rules-based difference in whether they're banned; both are. The practical difference is exposure duration. A no-DAC user dosing daily has drug in the system constantly but each dose clears fast; a DAC user dosing weekly has a long, slow-declining presence that a lab has more calendar time to catch. If you want the underlying pharmacology and study data in more depth, the CJC-1295 with DAC page walks through the original half-life study and what it does and doesn't establish about extended GH pulsatility.

Why is CJC-1295 usually paired with ipamorelin, and does that combination affect detection?

CJC-1295 is a GHRH analogue: it mimics growth hormone releasing hormone and tells the pituitary to release GH. Ipamorelin is a different class, a ghrelin receptor agonist (a GH secretagogue) that works through a separate receptor pathway and also suppresses somatostatin's braking effect on GH release. The rationale for stacking them is that they act on two different points in the same pathway, and in vitro and animal literature on GHRH-plus-GHRP combinations does show additive GH release compared to either alone ^[7]. That is genuinely studied pharmacology, more than forum lore. What is not established by that same literature is any clinical outcome data in healthy adults using this specific combination, off-label, at bodybuilding-forum doses, for muscle gain or fat loss. The foundational human studies on CJC-1295 and on ipamorelin were done at controlled clinical doses for specific endpoints (GH pulse amplitude, safety, in some cases pediatric growth hormone deficiency for related compounds), not for the self-administered protocols circulating online ^{[6] [1]}. Be skeptical of confident claims about how the combo behaves in the body long-term; the honest answer is it's plausible mechanistically and understudied practically. On detection: pairing the two doesn't average out or dilute anything. Ipamorelin is separately listed as a GH secretagogue under WADA S2, so combining it with CJC-1295 means an athlete has two independently prohibited substances in their system, each potentially flagged by its own assay or by the shared downstream effect on IGF-1 that the biological passport tracks.

Can CJC-1295 cause a false positive or a legitimate GH test to look abnormal?

Not a false positive in the sense of an error, but yes, it can and is meant to push GH-axis biomarkers into an abnormal range, because that's the pharmacological point of the drug. If you had legitimate clinical reasons to get bloodwork done, like an IGF-1 panel ordered by a physician for an unrelated concern, a recent CJC-1295 dose could elevate IGF-1 or GH readings and confuse interpretation of that unrelated test. This is a real clinical consideration, not a doping one, and it's a reason to tell your prescribing physician about any peptide use before routine labs. For sport testing specifically, an elevated IGF-1 or an abnormal GH isoform ratio isn't a "false" positive; it's the intended detection mechanism working as designed. The whole point of GH isoform and biomarker testing in anti-doping is to catch the downstream physiological signature of GH-axis stimulation, whether that stimulation came from injected recombinant GH, a GHRH analogue, or a GH secretagogue.

Is CJC-1295 legal to buy and possess outside of sports testing?

In the United States, CJC-1295 is not FDA-approved for any use in humans. It is sold, when sold legitimately, labeled "for research use only" or "not for human consumption," which is the same regulatory posture as most peptides in this space; it means no drug application has been approved by the FDA covering safety, purity, and efficacy in people ^[7]. That's a separate question from anti-doping status. A substance can be legal to possess for research purposes in a given state and still be strictly banned for a tested athlete under the WADA code. Athletes competing under a WADA-code sport, or a college/pro league with its own peptide-inclusive banned list, should assume any CJC-1295 use, regardless of its legal purchase status where they live, is a doping violation. Legal-to-buy and legal-to-compete-on are two different questions, and conflating them is one of the more common and costly mistakes reported in sanction cases involving supplements and peptides bought online.

What actually happens if an athlete tests positive for CJC-1295 or a GHRH analogue?

Under the World Anti-Doping Code, a positive test (an Adverse Analytical Finding) for a non-specified S2 substance like a GHRH analogue typically triggers a provisional suspension while the case is reviewed, followed by a formal results management process through the athlete's national anti-doping organization or international federation ^{[1] [8]}. Growth hormone and its releasing factors are classified as non-specified substances on the Prohibited List, which generally carries a stiffer standard sanction framework than specified substances under the Code's sanctioning provisions ^[8]. Standard first-violation sanctions under the current WADA Code run up to four years for non-specified substances absent a credible no-fault explanation, though actual outcomes vary by federation, evidence, and whether the athlete can establish the source and lack of intent ^[8]. This isn't a fine-and-move-on situation; it is career-altering for competitive athletes, which is exactly why the WADA-code ban and the biological passport monitoring exist in the first place.

Where does the bodybuilding-forum information about CJC-1295 detection come from, and can you trust it?

A lot of what circulates about CJC-1295 detection windows, dosing tricks to avoid testing, or claims that it's "undetectable" traces back to forum posts, retailer blog copy, and secondhand summaries with no citation trail back to an actual study or WADA document. Some of it isn't wrong by accident; it's optimistic marketing dressed as insider knowledge. The things that are genuinely established: CJC-1295's mechanism as a GHRH analogue, the DAC pharmacokinetic half-life data from the original published study, and WADA's explicit listing of GHRH analogues under S2 ^{[1] [6]}. The things that are not established anywhere in the peer-reviewed literature: specific detection-window numbers for recreational dosing patterns, clinical outcome data for the CJC-1295-plus-ipamorelin stack in healthy adults, and any claim that timing a dose a certain way reliably beats the biological passport. If a source states a precise detection window in days without citing a study, that number came from somewhere other than science. For readers who want the underlying evidence base rather than forum consensus, the main CJC-1295 hub page separates what's actually been studied from what's repeated online without support, and the CJC-1295 side effects page covers the safety data (and gaps in it) in the same spirit.

How should someone researching CJC-1295 think about sourcing, given the legal and testing landscape?

If you're not a tested athlete and you're researching CJC-1295 for personal reasons, the testing question is mostly moot; there's no employer or DOT panel screening for it, as covered above. What still matters is sourcing quality, because the research-use-only market has real variability in purity and actual peptide content between suppliers. CJC-1295 Co reviews providers and points readers toward a provider-reviewed sourcing path with a named fulfilling pharmacy partner, rather than compounding or selling anything directly; the CJC-1295 for sale page walks through what that review process looks for. If you are a tested athlete, the sourcing question is secondary to the simple fact that any GHRH analogue use, however it was obtained, is a Prohibited List violation regardless of purity or supplier reputation.

How does CJC-1295 dosing relate to the testing and biomarker picture?

Dose and frequency directly affect how long a detectable signature persists, both for direct peptide detection and for the biomarker shifts the Athlete Biological Passport tracks. Higher or more frequent dosing produces a bigger, longer IGF-1 and GH pulse-amplitude disturbance, which is exactly the kind of pattern longitudinal passport testing is built to flag over months, more than on test day. The practical dosing protocols discussed in clinical and semi-clinical literature (and the ones covered in more detail on the CJC-1295 dosage page and the CJC-1295 DAC dosage calculator) are built around achieving a target GH pulse pattern, not around evading detection; anyone reverse-engineering a dosing schedule specifically to beat a drug test is working from an assumption (that timing beats the passport) that isn't well supported.

Frequently asked questions

Is CJC-1295 banned by WADA?

Yes. CJC-1295 is a GHRH analogue and falls under WADA's S2 category, "Growth Hormone (GH) and its releasing factors," which is banned at all times, in and out of competition, for any athlete under the WADA Code ^[1].

Will CJC-1295 show up on a standard workplace or DOT drug test?

No. Standard 5- or 10-panel workplace tests and DOT Part 40 panels screen for substances like THC, cocaine, opiates, and amphetamines using assays that don't detect peptide hormones. CJC-1295 requires a specific mass-spec method that only WADA-accredited anti-doping labs typically run ^[2].

How long does CJC-1295 stay detectable in the body?

No published, universally-cited number exists. CJC-1295 without DAC has roughly a 30-minute half-life, so direct detection likely closes within about a day. CJC-1295 with DAC has a published half-life around 6 to 8 days, so detectable drug can plausibly persist one to two weeks or more ^[5][6].

What's the difference between CJC-1295 with DAC and without DAC for testing purposes?

Both fall under the same WADA S2 category and are equally prohibited. The practical difference is pharmacokinetic: DAC binds serum albumin and extends the half-life to about a week, versus roughly 30 minutes without it, giving labs a longer window to catch it ^[6].

Does taking ipamorelin with CJC-1295 change detection risk?

No, it increases it if anything. Ipamorelin is separately classified as a GH secretagogue under WADA S2, so combining it with CJC-1295 means two independently prohibited substances, each potentially flagged on its own or through the shared IGF-1 biomarker effect tracked by the Athlete Biological Passport ^[1][3].

Can the Athlete Biological Passport catch CJC-1295 use even without a positive drug test?

Yes, that's largely its purpose for GH-axis doping. The ABP tracks individual biomarkers like IGF-1 and GH-related markers over time; a pattern inconsistent with an athlete's own established baseline can support an anti-doping case even without directly detecting the peptide itself ^[3][4].

Is CJC-1295 legal to buy in the United States?

It is not FDA-approved for human use and is typically sold labeled for research use only, meaning no FDA-reviewed safety or efficacy data backs it for people ^[9]. Legal purchase status is separate from sport eligibility; a WADA-code athlete using it is still in violation regardless of how it was bought.

What happens if an athlete tests positive for a GHRH analogue like CJC-1295?

It typically triggers a provisional suspension and a formal results management process. GH and its releasing factors are non-specified substances on the Prohibited List, which generally carries standard sanctions of up to four years for a first violation absent a credible no-fault explanation, per the WADA Code ^[1][10].

Why do people pair CJC-1295 with ipamorelin instead of using either alone?

CJC-1295 stimulates the GHRH receptor while ipamorelin acts on the ghrelin receptor and blunts somatostatin, a separate braking mechanism on GH release. Combined GHRH-plus-GHRP dosing has shown additive GH output in pharmacology studies, though clinical outcome data for this specific self-administered stack in healthy adults is limited ^[7].

Can CJC-1295 cause an abnormal result on a routine medical GH or IGF-1 test?

It can meaningfully raise IGF-1 or affect GH pulse readings on a legitimate clinical blood panel, since that's the pharmacological effect of the drug. It's worth disclosing any peptide use to a physician ordering bloodwork so results aren't misread as an unrelated endocrine issue.

Are the detection-window numbers on bodybuilding forums accurate?

Usually not verifiable. Specific day-count detection claims for recreational dosing patterns generally aren't backed by any published pharmacokinetic study. The only solid numbers come from the original DAC half-life study (about 6 to 8 days) and general knowledge of the no-DAC peptide's short plasma half-life ^[6].

Does CJC-1295 use count as doping even outside of a competition period?

Yes. S2 substances are banned both in-competition and out-of-competition under the WADA Code, so there is no off-season window where GHRH analogue use is permitted for a tested athlete ^[1].

Sources

1. World Anti-Doping Agency, 2024 Prohibited List: CJC-1295 and other GHRH analogues are listed under S2, banned in and out of competition
2. U.S. Department of Transportation, 49 CFR Part 40: DOT drug testing regulations specify the substances tested for, which do not include peptide GH secretagogues
3. World Anti-Doping Agency, Athlete Biological Passport Operating Guidelines: The Athlete Biological Passport tracks longitudinal biomarkers to detect doping patterns rather than a single substance
4. World Anti-Doping Agency, Guidelines for Growth Hormone Isoform Testing: GH isoform and biomarker testing methods are used to detect growth hormone doping
5. National Center for Biotechnology Information, PubChem Compound Summary: Structural and pharmacological identity of CJC-1295 as a GHRH analogue
6. Teichman SL et al., Journal of Clinical Endocrinology & Metabolism, 2006: CJC-1295 with DAC has a half-life of approximately 6 to 8 days and sustains elevated GH and IGF-1 levels
7. U.S. Food and Drug Administration, FDA and Unapproved Drugs / Compounded Drug guidance: Peptides like CJC-1295 sold for research use only are not FDA-approved for human use
8. World Anti-Doping Agency, World Anti-Doping Code 2021: Standard sanctions for non-specified substance violations and results management process